JPH08187086A - Purification of viral gene - Google Patents
Purification of viral geneInfo
- Publication number
- JPH08187086A JPH08187086A JP252495A JP252495A JPH08187086A JP H08187086 A JPH08187086 A JP H08187086A JP 252495 A JP252495 A JP 252495A JP 252495 A JP252495 A JP 252495A JP H08187086 A JPH08187086 A JP H08187086A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- viral
- solution
- protein
- hollow fiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108700005077 Viral Genes Proteins 0.000 title claims abstract description 31
- 238000000746 purification Methods 0.000 title description 5
- 241000700605 Viruses Species 0.000 claims abstract description 50
- 239000012528 membrane Substances 0.000 claims abstract description 30
- 239000012510 hollow fiber Substances 0.000 claims abstract description 21
- 238000001914 filtration Methods 0.000 claims abstract description 20
- 108010067390 Viral Proteins Proteins 0.000 claims abstract description 14
- 239000011148 porous material Substances 0.000 claims abstract description 12
- 239000002245 particle Substances 0.000 claims abstract description 8
- 230000003612 virological effect Effects 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 21
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 27
- 102000004169 proteins and genes Human genes 0.000 abstract description 20
- 239000004627 regenerated cellulose Substances 0.000 abstract description 6
- 108091005804 Peptidases Proteins 0.000 abstract description 5
- 238000004925 denaturation Methods 0.000 abstract description 4
- 230000036425 denaturation Effects 0.000 abstract description 4
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 238000000354 decomposition reaction Methods 0.000 abstract description 2
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000035699 permeability Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 102220201851 rs143406017 Human genes 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- QKSIFUGZHOUETI-UHFFFAOYSA-N copper;azane Chemical compound N.N.N.N.[Cu+2] QKSIFUGZHOUETI-UHFFFAOYSA-N 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000012290 Total DNA Assay Methods 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、ウイルス遺伝子の精製
方法、詳しくは遺伝子工学分野・遺伝子治療分野・ウイ
ルス検査において用いられるウイルス遺伝子(DNA及
びRNA)の精製方法に関する。TECHNICAL FIELD The present invention relates to a method for purifying viral genes, and more particularly to a method for purifying viral genes (DNA and RNA) used in the fields of genetic engineering, gene therapy and virus testing.
【0002】[0002]
【従来の技術】近年、遺伝子工学技術の進歩に伴い、ウ
イルス遺伝子の塩基配列解析・遺伝子治療分野におい
て、遺伝子組み替えによるウイルスベクタ−の作製、さ
らにはウイルス遺伝子を増幅するPCR法(Polym
erase Chain Reaction法)を利用
したウイルス検査が行なわれており、そのため、ウイル
ス遺伝子の精製が必要となってきた。2. Description of the Related Art In recent years, with the progress of genetic engineering technology, in the fields of nucleotide sequence analysis and gene therapy of viral genes, viral vectors are prepared by gene recombination, and further, PCR method (Polym) for amplifying viral genes is carried out.
A virus test using the erase chain reaction method) has been carried out, and thus purification of viral genes has become necessary.
【0003】水溶液からのウイルスの濃縮・精製法とし
ては、低速遠心と高速遠心を組み合わせて粒子の大きさ
によって分離する方法やポリエチレングリコ−ル(PE
G)のようなポリマ−を用いてウイルスを沈澱後濃縮さ
せ、透析により高濃度のPEGを除去する方法が行われ
ていた。しかしながら、前者は高価な遠心装置が必要で
あること及び遠心時間がかかるという問題、後者は透析
に時間がかかる上に、共存するタンパクもウイルスとと
もに沈殿させてしまうという問題があった。また、危険
度の高いウイルス使用時には操作が煩雑であることから
問題があった。As a method for concentrating and purifying viruses from an aqueous solution, a method of separating the particles according to the size of particles by combining low-speed centrifugation and high-speed centrifugation or polyethylene glycol (PE
A method of precipitating and concentrating a virus using a polymer such as G) and removing high concentration of PEG by dialysis has been performed. However, the former has a problem that an expensive centrifuge is required and it takes a long time to centrifuge, and the latter has a problem that dialysis takes time and a coexisting protein is precipitated together with the virus. In addition, there is a problem because the operation is complicated when using a virus having a high degree of risk.
【0004】一方、ウイルス遺伝子の分離・精製法とし
ては、ウイルス液をフェ−ノル抽出で、タンパク変性す
る方法や、ラウリル硫酸ナトリウム(SDS)やサルコ
シ−ルといった界面活性剤処理、プロテア−ゼKのよう
なタンパク分解酵素を用いる方法や、アルカリ金属水酸
化物水溶液を用いたアルカリ変性処理、加熱処理があ
り、場合によってはこれらの処理を組み合わせて行なっ
ている。On the other hand, as a method of separating and purifying viral genes, a method of protein denaturation of a virus solution by phenol extraction, a treatment with a surfactant such as sodium lauryl sulfate (SDS) or sarcosyl, and a protease K are used. There is a method using such a proteolytic enzyme, an alkali denaturation treatment using an alkali metal hydroxide aqueous solution, and a heat treatment, and in some cases, these treatments are combined.
【0005】水溶液からのウイルスの濃縮・精製工程の
後、ウイルス遺伝子の分離・精製工程を行うことは、こ
れらの工程が独立した系であるため、さらに操作が煩雑
になるという問題があった。かかる問題を解決するため
に、例えば特開平3−180182号公報には微生物培
養液中のファ−ジの遺伝子の精製法において微生物菌体
を孔径が0.45μmないし0.22μmであるメンブ
レンフィルタ−で濾過除去後、その濾液をタンパク分解
酵素処理等で処理し、ファージタンパク質を分解・変性
させた後、分画分子量2万〜100万の範囲の限外濾過
膜で濾過することでタンパク・不純物を除去し、ファ−
ジ遺伝子を得るか、又はフィルタ−で微生物菌体を除去
後、その濾液を限外濾過膜で濾過し、共存する小分子量
物質を除いてファージを限外濾過膜上で精製し、タンパ
ク分解酵素処理等で処理する方法が開示されている。There is a problem that performing the virus gene separation / purification process after the virus concentration / purification process from the aqueous solution further complicates the operation because these processes are independent systems. In order to solve such a problem, for example, in Japanese Unexamined Patent Publication No. 3-180182, in a method for purifying a gene of a phage in a microbial culture solution, a microbial cell is a membrane filter having a pore size of 0.45 μm to 0.22 μm. After removal by filtration with a filter, the filtrate is treated with proteolytic enzyme, etc. to decompose and denature the phage protein, and then filtered through an ultrafiltration membrane having a molecular weight cut-off of 20,000 to 1,000,000 to obtain proteins and impurities. To remove the
After obtaining the digene or removing the microbial cells with a filter, the filtrate is filtered through an ultrafiltration membrane to remove coexisting small molecular weight substances, and the phage is purified on the ultrafiltration membrane. A method of processing by processing or the like is disclosed.
【0006】しかしながら、限外濾過膜で濾過する方法
では目詰まりが起こり易いことから、濾過速度が遅く、
処理容量が高くないことや、その結果ウイルスの遺伝子
以外にも混在している大きなタンパクや菌体断片や菌体
由来の遊離した裸の遺伝子がかなり高い割合で混入して
いるという問題があった。However, in the method of filtering with an ultrafiltration membrane, clogging easily occurs, so that the filtration rate is slow,
There was a problem that the processing capacity was not high, and as a result, a large proportion of large proteins, bacterial fragments, and free naked genes derived from bacterial cells that were mixed with other than viral genes were contaminated. .
【0007】[0007]
【発明が解決しようとする課題】本発明の課題は、大量
のタンパク水溶液から繁雑な操作をできるだけ省き、短
時間にウイルスを濃縮後、高純度のウイルス遺伝子を精
製することである。SUMMARY OF THE INVENTION An object of the present invention is to purify highly pure viral genes after concentrating viruses in a short time while avoiding complicated operations from a large amount of protein aqueous solution as much as possible.
【0008】[0008]
【課題を解決するための手段】本発明者らは、上記課題
を解決すべく鋭意努力した結果本発明に至った。すなわ
ち本発明は、ウイルスが混入又はウイルスを含有してい
る溶液を平均孔径が10nm以上200nm以下である
多孔性中空糸膜で濾過して濃縮ウイルス液を得る工程
と、該濃縮ウイルス液中のウイルスのウイルスタンパク
を変性させてウイルス遺伝子とウイルスタンパクに分解
する工程とを含むウイルス遺伝子の精製方法である。以
下、その内容について説明する。[Means for Solving the Problems] The present inventors have accomplished the present invention as a result of diligent efforts to solve the above problems. That is, the present invention comprises a step of obtaining a concentrated virus solution by filtering a solution containing a virus or containing a virus through a porous hollow fiber membrane having an average pore size of 10 nm or more and 200 nm or less, and a virus in the concentrated virus solution. Is a method for purifying a viral gene, which comprises a step of denaturing the viral protein to decompose it into a viral gene and a viral protein. The contents will be described below.
【0009】本発明において濾過に用いる多孔性中空糸
膜は、タンパク溶液からウイルスを捕捉してタンパクを
透過させるために、除去すべきウイルスの大きさとの関
係から後述の方法により測定した平均孔径孔径が10n
m〜200nmの範囲であることが必要である。10n
m未満ではタンパク透過性が著しく低下し、200nm
を超えるとウイルスの除去性能が著しく低下する。The porous hollow fiber membrane used for filtration in the present invention has a mean pore diameter and a pore diameter measured by the method described below in relation to the size of the virus to be removed in order to capture the virus from the protein solution and allow the protein to permeate. Is 10n
It is necessary to be in the range of m to 200 nm. 10n
If it is less than m, the protein permeability is remarkably reduced, and 200 nm
If it exceeds, the virus removal performance is significantly reduced.
【0010】さらに、対象となるウイルス粒子の径の大
きさに応じて、適切な孔径を選択する。すなわち、ウイ
ルス粒子径以下の孔径を持つフィルタ−を選択するとよ
い。特開昭61−254202号公報、特開昭61−2
547027号公報、特開平4−371221号公報に
代表される銅アンモニア法再生セルロ−ス多孔性中空糸
膜は、平均孔径15、35、75nmのフィルタ−が市
販されている。また、ウイルス混入液が細胞破砕液や、
細胞培養液や血液など、多量の大きな夾雑物質が混入し
ているものの場合、孔径35nm〜0.45μmのフイ
ルタ−で予め濾過し、多量の大きな夾雑物質を除いた
後、ウイルス濃縮のための濾過をおこなえば、濾過処理
の時間が短縮され、より純度の高いウイルスの精製が行
なえる。Further, an appropriate pore size is selected according to the size of the target virus particle. That is, it is advisable to select a filter having a pore size equal to or smaller than the virus particle size. JP-A-61-254202, JP-A-61-2
As the copper-ammonia method regenerated cellulose porous hollow fiber membranes represented by JP-A-547027 and JP-A-4-371221, filters having an average pore diameter of 15, 35 and 75 nm are commercially available. In addition, the virus contaminated solution is a cell lysate,
When a large amount of large contaminants such as cell culture medium and blood are mixed, it is filtered in advance with a filter having a pore size of 35 nm to 0.45 μm to remove the large amount of large contaminants, and then filtered for virus concentration. If this is done, the time of the filtration process can be shortened, and a virus of higher purity can be purified.
【0011】本発明において濾過に用いる多孔性中空糸
膜は、ウイルス捕捉可能な膜厚が10μm以上100μ
m以下であることが好ましい。10μm未満ではウイル
スの除去率が低下し、100μmを超えるとタンパク質
の透過率が低下する。ここで、ウイルス除去性能の良い
とは、日本脳炎ウイルス(粒子径約45nm)の対数除
去性能(LRV)で4以上であること、タンパク透過率
が高いとは、例えばアルブミンの透過率が90%以上で
あることを意味する。なお、LRVは以下のように定義
される値である。The porous hollow fiber membrane used for filtration in the present invention has a film thickness capable of capturing viruses of 10 μm or more and 100 μm or more.
m or less. If it is less than 10 μm, the virus removal rate is lowered, and if it exceeds 100 μm, the protein permeability is lowered. Here, good virus removal performance means that the logarithmic removal performance (LRV) of Japanese encephalitis virus (particle diameter of about 45 nm) is 4 or more, and high protein permeability means that albumin permeability is 90%, for example. It means that it is above. LRV is a value defined as follows.
【0012】LRV = log10(No/Nf) No;濾過前の元液中のウイルス濃度 Nf;濾過後の濾液中のウイルス濃度 本発明において濾過に用いる多孔性中空糸膜は膜厚方向
にかけて層状構造を有していることが好ましい。LRV = log 10 (N o / N f ) N o ; virus concentration in the original solution before filtration N f ; virus concentration in the filtrate after filtration The porous hollow fiber membrane used for filtration in the present invention is a membrane. It is preferable to have a layered structure in the thickness direction.
【0013】本発明において濾過に用いる多孔性中空糸
膜は、目詰まりを少なくし、高い透過速度を保つために
は、膜厚方向にかけて平均空孔率が0.3以上0.6以
下であることが好ましい。ここで、空孔率(Pr )は以
下の方法で算出するものとする。 Pr =1−ρa /ρp Pr :空孔率(−) ρa :水膨潤時の見かけ密度 ρp :ポリマ−密度(セルロ−スの場合、1.561g
/cm3 ) 本発明において濾過に用いる多孔性中空糸膜の素材とし
ては、ポリフッ化ビニリデン、再生セルロース、セルロ
−ス、セルロ−スアセテ−ト、ポリスルフォン、ビニル
クロライド、ポリエステル、ポリメチルメタクリレ−
ト、アクリロニトリル、ナイロンを用いることができ
る。これらのうち、タンパク水溶液中のウイルス粒子を
除去するには親水性高分子を用いることが好ましく、濾
過性能・タンパクの透過性の点からは再生セルロースが
特に好ましい。これはタンパクと高分子素材との吸着に
関する相関性を検討した結果、親水性素材ほどタンパク
の吸着性が小さいため本発明の素材としてより好まし
く、なかでも再生セルロースが特に好ましいためと思わ
れる。The porous hollow fiber membrane used for filtration in the present invention has an average porosity of 0.3 to 0.6 in the thickness direction in order to reduce clogging and maintain a high permeation rate. It is preferable. Here, the porosity (P r ) is calculated by the following method. P r = 1-ρ a / ρ p P r : Porosity (-) ρ a : Apparent density when swollen in water ρ p : Polymer density (1.561 g in the case of cellulose)
/ Cm 3 ) The material of the porous hollow fiber membrane used for filtration in the present invention includes polyvinylidene fluoride, regenerated cellulose, cellulose, cellulose acetate, polysulfone, vinyl chloride, polyester, polymethylmethacrylate.
Glycine, acrylonitrile, or nylon can be used. Of these, hydrophilic polymers are preferably used to remove virus particles in the protein aqueous solution, and regenerated cellulose is particularly preferable from the viewpoint of filtration performance and protein permeability. As a result of investigating the correlation regarding the adsorption between the protein and the polymer material, it is considered that the hydrophilic material is more preferable as the material of the present invention because the protein adsorption is smaller, and regenerated cellulose is particularly preferable.
【0014】本発明の方法において、濾過圧力は0.1
〜1気圧であることが好ましい。0.1気圧未満では蛋
白質の透過性は増大するが、ウイルスの除去性は低下す
る傾向がある。さらに、PBS等の緩衝液でウイルス濾
過後のフィルタ−を洗浄すると、さらに夾雑タンパクや
溶解した裸のDNAを除くことができる。効果的な遊離
DNA・RNAの除去のためには、濾過前のサンプルに
DNase・RNaseを加えてDNA・RNAの分解
反応をあらかじめ行なってもよい。In the method of the present invention, the filtration pressure is 0.1.
It is preferably -1 atm. If the pressure is less than 0.1 atm, the protein permeability will increase, but the virus removability tends to decrease. Furthermore, by washing the filter after virus filtration with a buffer such as PBS, it is possible to further remove contaminating proteins and dissolved naked DNA. In order to effectively remove free DNA / RNA, DNA / RNA degradation reaction may be performed in advance by adding DNase / RNase to the sample before filtration.
【0015】本発明においてウイルスタンパクを変性・
分解する方法は、中空糸膜上にウイルスを捕捉させたま
ま行なうこともできるし、濃縮ウイルス液を中空糸膜か
ら回収して行なうこともできる。中空糸膜にウイルスを
捕捉させたまま行なう方法としては、例えばタンパク分
解酵素を用いる方法や、界面活性剤による方法、アルカ
リ変性処理、加熱処理がある。また、濃縮ウイルス液を
膜から回収した場合には、上記方法に加えて、フェノ−
ル処理も行なうことができる。場合によっては、これら
の処理を組み合わせて行なってもよい。これらの処理に
より、ウイルスタンパクは変性され、ウイルス遺伝子
は、ウイルスタンパクと分離される。In the present invention, the viral protein is denatured
The method of decomposition can be carried out while the virus is trapped on the hollow fiber membrane, or the concentrated virus solution can be recovered from the hollow fiber membrane. Examples of the method performed while the virus is captured on the hollow fiber membrane include a method using a proteolytic enzyme, a method using a surfactant, an alkali denaturation treatment, and a heat treatment. When the concentrated virus liquid is recovered from the membrane, in addition to the above method,
Processing can also be performed. In some cases, these processes may be combined. By these treatments, the viral protein is denatured and the viral gene is separated from the viral protein.
【0016】次いで、緩衝液、例えばTE緩衝液(Tr
is−HCl緩衝液EDTA)等を用いて、中空糸膜を
濾過することで洗浄処理し、ウイルス遺伝子溶液を得る
ことができる。その液を用いてPCR反応を行なうこと
もできるし、さらに、共存しているわずかなタンパクを
除去して、ウイルス遺伝子の精製度を上げるために、限
外濾過法やイオン交換法を行なうこともできる。必要に
応じてこのウイルス遺伝子溶液を従来のエタノ−ル沈殿
処理により、濃縮することができる。Next, a buffer solution such as TE buffer solution (Tr
The virus gene solution can be obtained by washing the hollow fiber membrane with is-HCl buffer EDTA) or the like for filtration. A PCR reaction can be performed using the solution, or an ultrafiltration method or an ion exchange method can be performed in order to remove a small amount of coexisting proteins and improve the purification degree of viral genes. it can. If necessary, this viral gene solution can be concentrated by a conventional ethanol precipitation treatment.
【0017】[0017]
【0018】[0018]
【実施例1】ハイブリド−マ細胞で培養した細胞培養液
から細胞画分を除いた上清液に大腸菌ファ−ジΦX17
4をスパイクした。平均孔径35nm、ウイルス捕捉可
能な膜厚35μm、平均空孔率0.5の銅アンモニア法
再生セルロ−ス多孔性中空糸膜(BMM)を用い、圧力
200mmHgにてこの液を濾過し、下記(1)式によ
りタンパク・遊離したDNA・ΦX174の透過率を求
めた。なお、溶液中のタンパク量はバイオ ラド プロ
テイン アッセイ キット(バイオラド社)、遊離した
DNA量は、スレッシュホ−ルド総DNA アッセイシ
ステム(モレキュラ−ディバイス社)、ΦX174の濃
度はプラ−ク法にて測定した。以上の結果を表1に示
す。Example 1 Escherichia coli phage ΦX17 was added to a supernatant obtained by removing cell fractions from a cell culture solution cultured with hybridoma cells.
I spiked 4. This solution was filtered at a pressure of 200 mmHg using a copper ammonia method regenerated cellulose porous hollow fiber membrane (BMM) having an average pore diameter of 35 nm, a film thickness capable of capturing viruses of 35 μm, and an average porosity of 0.5, and the following ( The transmittance of protein, released DNA, and ΦX174 was calculated by the formula (1). The amount of protein in the solution was measured by Bio-Rad Protein Assay Kit (Bio-Rad), the amount of released DNA was measured by Threshold Hold Total DNA Assay System (Molecular Devices), and the concentration of ΦX174 was measured by the plaque method. . Table 1 shows the above results.
【0019】 透過率=濾液中の濃度/元液中の濃度 (1)Permeability = concentration in filtrate / concentration in original solution (1)
【0020】[0020]
【表1】 [Table 1]
【0021】ウイルスを捕捉したフィルタ−上で、タン
パク分解酵素プロテア−ゼkでタンパク分解処理した。
さらにフィルタ−をPBSで洗浄し、その液で、ウイル
ス遺伝子に特異な配列を持ったプライマ−を用いて、P
CR反応(Saki,R.K.et al,Scien
ce 239 487−491(1988))を行っ
た。同時にウイルス遺伝子の市販標準品(宝酒造社製)
も同一のプライマ−でPCR反応を行なった。各サンプ
ルは、定法に従い、電気泳動をおこなった。レ−ン1
は、pUC18を制限酵素HaeIIIで切断して得ら
れた分子量マ−カ−、レ−ン2は、実施例1から精製し
たサンプルをPCR反応を行なったもの、レ−ン3は、
市販標準品をPCR反応を行なったものである。その結
果を図1に示す。その結果、本方法によれば、簡便に高
い純度でウイルス遺伝子を精製できることが解った。On the filter which captured the virus, proteolytic treatment was carried out with proteolytic enzyme Protease k.
Further, the filter was washed with PBS, and the solution was treated with a primer having a sequence specific to the viral gene to give P
CR reaction (Saki, RK et al, Scien
ce 239 487-491 (1988)). At the same time, a commercial standard of viral genes (Takara Shuzo)
PCR reaction was also performed with the same primer. Each sample was subjected to electrophoresis according to a standard method. Lane 1
Is a molecular weight marker obtained by cleaving pUC18 with a restriction enzyme HaeIII, lane 2 is obtained by subjecting the sample purified from Example 1 to PCR reaction, and lane 3 is
A commercially available standard product was subjected to PCR reaction. The result is shown in FIG. As a result, it was found that the present method can easily purify a viral gene with high purity.
【0022】[0022]
【発明の効果】本発明によれば、濾過フィルターでタン
パク溶液中のウイルスを簡便に短時間で大量に高い純度
で濃縮後、ウイルス遺伝子を精製することができる。INDUSTRIAL APPLICABILITY According to the present invention, the virus in the protein solution can be easily concentrated in a short time in a large amount with a high purity using a filtration filter, and then the viral gene can be purified.
【図1】本発明の実施例1により精製されたウイルス遺
伝子の電気泳動パタ−ンを従来法により精製されたウイ
ルス遺伝子、市販のウイルス遺伝子の電気泳動パタ−ン
と共に示す図である。FIG. 1 is a diagram showing an electrophoretic pattern of a viral gene purified according to Example 1 of the present invention, together with a viral gene purified by a conventional method and an electrophoretic pattern of a commercially available viral gene.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 C12R 1:92) (C12N 7/00 C12R 1:92) C12R 1:92) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI technical display location C12R 1:92) (C12N 7/00 C12R 1:92) C12R 1:92)
Claims (5)
いる溶液を平均孔径が10nm以上200nm以下であ
る多孔性中空糸膜で濾過して濃縮ウイルス液を得る工程
と、該濃縮ウイルス液中のウイルスのウイルスタンパク
を変性させてウイルス遺伝子とウイルスタンパクに分解
する工程とを含むウイルス遺伝子の精製方法。1. A step of obtaining a concentrated virus solution by filtering a solution containing a virus or containing a virus through a porous hollow fiber membrane having an average pore diameter of 10 nm or more and 200 nm or less, and the virus in the concentrated virus solution. A method for purifying a viral gene, which comprises the step of denaturing the viral protein to decompose the viral protein into a viral protein.
る膜中の厚さが10μm以上100μm以下である請求
項1記載のウイルス遺伝子の精製方法。2. The method for purifying a viral gene according to claim 1, wherein the hollow fiber membrane has a thickness of 10 μm or more and 100 μm or less in the membrane for capturing virus particles.
糸膜上でウイルスタンパクを変性させてウイルス遺伝子
とウイルスタンパクに分解し、更に該中空糸膜を水溶液
で洗浄してウイルス遺伝子を回収する請求項1又は2記
載のウイルス遺伝子の精製方法。3. After carrying out the filtration on a hollow fiber membrane, the viral protein is denatured on the hollow fiber membrane to decompose into viral genes and viral proteins, and the hollow fiber membrane is washed with an aqueous solution to obtain viral genes. The method for purifying a viral gene according to claim 1 or 2, wherein the virus is recovered.
した後、溶液中でウイルスのウイルスタンパクを変性さ
せてウイルス遺伝子とウイルスタンパクに分解する請求
項1又は2記載のウイルス遺伝子の精製方法。4. The method for purifying a viral gene according to claim 1, wherein the concentrated viral liquid is recovered from the hollow fiber membrane, and then the viral viral protein is denatured in the solution to decompose into a viral gene and a viral protein.
0.3以上0.6以下である請求項1〜4いずれかに記
載のウイルス遺伝子の精製方法。5. The method for purifying a viral gene according to claim 1, wherein the hollow fiber membrane has an average porosity in the membrane direction of 0.3 or more and 0.6 or less.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP252495A JPH08187086A (en) | 1995-01-11 | 1995-01-11 | Purification of viral gene |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP252495A JPH08187086A (en) | 1995-01-11 | 1995-01-11 | Purification of viral gene |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08187086A true JPH08187086A (en) | 1996-07-23 |
Family
ID=11531775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP252495A Withdrawn JPH08187086A (en) | 1995-01-11 | 1995-01-11 | Purification of viral gene |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH08187086A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999007458A1 (en) * | 1997-08-06 | 1999-02-18 | Genentech, Inc. | Hollow fiber co-flow filtration device |
US5989431A (en) * | 1995-06-08 | 1999-11-23 | Progen Industries Ltd | Method and apparatus for DNA extraction |
WO2002070689A1 (en) * | 2001-03-07 | 2002-09-12 | Nix, Inc. | Method of extracting virus gene and extraction apparatus |
EP2199319A1 (en) | 2008-12-19 | 2010-06-23 | Gambro Lundia AB | Virus filter |
-
1995
- 1995-01-11 JP JP252495A patent/JPH08187086A/en not_active Withdrawn
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5989431A (en) * | 1995-06-08 | 1999-11-23 | Progen Industries Ltd | Method and apparatus for DNA extraction |
WO1999007458A1 (en) * | 1997-08-06 | 1999-02-18 | Genentech, Inc. | Hollow fiber co-flow filtration device |
WO2002070689A1 (en) * | 2001-03-07 | 2002-09-12 | Nix, Inc. | Method of extracting virus gene and extraction apparatus |
US7267952B2 (en) | 2001-03-07 | 2007-09-11 | Nix, Inc. | Method of extracting virus genes and extraction apparatus |
EP2199319A1 (en) | 2008-12-19 | 2010-06-23 | Gambro Lundia AB | Virus filter |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6365395B1 (en) | Process for removing protein aggregates and virus from a protein solution | |
CA2261150C (en) | Methods for purifying nucleic acids | |
US20020090623A1 (en) | Transfusion medicine leukodepletion filter devices as a source of genetic material for genotyping studies | |
CA2296733A1 (en) | Methods for purifying viral nucleic acids using a hydrophilic polyvinylidine fluoride (pvdf) membrane | |
JP2002515508A (en) | Method and apparatus for purifying nucleic acid | |
JP2978518B2 (en) | Method for purifying phage DNA | |
JPH04360686A (en) | Purification of dna | |
JP5080713B2 (en) | Method for producing virus-removed plasma protein composition by porous membrane treatment, virus-removed plasma protein composition, and virus removal method | |
US4863609A (en) | Process for the fractional separation of protein mixtures by means of membranes | |
EP0240191A2 (en) | Method of isolating DNA contained in a virus or cell | |
JPH08187086A (en) | Purification of viral gene | |
JP4646114B2 (en) | Plasma preparation or serum preparation and method for producing the same | |
JP3547715B2 (en) | Apparatus and method for vector purification | |
Higuchi et al. | Rejection of single stranded and double stranded DNA by porous hollow fiber membranes | |
JPH0823976A (en) | Purification of plasmid dna having super-coil form | |
KR100624447B1 (en) | Method for Purifying Nucleic Acids Using Silver Nanoparticles | |
JP3371783B2 (en) | Cell isolation method | |
JP3108463B2 (en) | DNA purification method | |
JP2000005569A (en) | Series multistage filtration method | |
JPH10155481A (en) | DNA recovery method | |
JPH06238141A (en) | Filter membrane | |
JP2948675B2 (en) | Cross-flow filtration method for recovering valuable materials in fermentation liquor | |
JP2000319294A (en) | Purification of solution of polymer originating from organism | |
JP2004089155A (en) | Method for purifying aqueous solution of protein | |
CN116966285A (en) | Purification buffer solution composition and purification method of foot-and-mouth disease inactivated vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20020402 |